C7orf28A Inhibitors
C7orf28A inhibitors encompass a range of chemical compounds that, through their distinct mechanisms of action, contribute to the suppression of C7orf28A activity. For instance, staurosporine, a broad-spectrum kinase inhibitor, may indirectly inhibit the activity of C7orf28A by modifying the phosphorylation states of proteins within the signaling pathways that C7orf28A is involved in. Similarly, the PI3K inhibitors LY294002 and wortmannin can prevent the activation of the PI3K/AKT pathway, potentially disrupting the functional activity of downstream proteins that interact with C7orf28A. Inhibitors such as rapamycin, targeting the mTOR signaling pathway, may lead to reduced protein synthesis and indirectly decrease C7orf28A activity, while the proteasome inhibitor bortezomib can induce a cellular stress response, potentially affecting C7orf28A function as a secondary consequence of proteostasis disruption.
Furthermore, inhibitors specific to various kinases and phosphatases can alter the cellular signaling milieu in ways that might impact C7orf28A. Trichostatin A, which inhibits histone deacetylases, could change the gene expression landscape, thereby affecting C7orf28A indirectly. PD98059 and U0126, both MEK inhibitors, disrupt the MAPK/ERK pathway, influencing cellular proliferation and differentiation processes that could lead to decreased activity of C7orf28A. SB203580, targeting p38 MAPK, and SP600125, a JNK inhibitor, may attenuate inflammatory responses and apoptosis, affecting C7orf28A activity. Cyclosporin A's inhibition of calcineurin might result in reduced NFAT-mediated signaling, potentially diminishing C7orf28A's activity. Lastly, ZM-447439's role in hindering Aurora kinase function and subsequent impact on cell cycle progression offers another avenue by which C7orf28A activity could be indirectly diminished, emphasizing the versatility and specificity with which these inhibitors can modulate the molecular context of C7orf28A function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that can inhibit a wide range of protein kinases. Inhibition of these kinases can lead to downstream effects that may include the functional inhibition of C7orf28A due to altered phosphorylation states. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of PI3K, which is part of the PI3K/AKT signaling pathway. Inhibition of this pathway can affect the activity of downstream proteins that interact with C7orf28A, potentially leading to decreased functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can prevent the activation of the mTOR pathway. As mTOR is involved in protein synthesis and cell growth, inhibiting this pathway could indirectly decrease the functional activity of C7orf28A. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor which can alter gene expression profiles. Such changes in gene expression could indirectly influence the expression or function of C7orf28A. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor that disrupts the MAPK/ERK pathway. This pathway is involved in cell proliferation and differentiation, and its inhibition could lead to an indirect decrease in C7orf28A activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can lead to the accumulation of proteins marked for degradation. This can cause a stress response that may impact the function of various proteins including C7orf28A. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
An immunosuppressant that inhibits calcineurin. By inhibiting this phosphatase, cyclosporin A can affect the NFAT signaling pathway, which could lead to an indirect reduction in C7orf28A functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that can suppress the p38 MAPK pathway, which is involved in stress responses and inflammation. Inhibition of this pathway could lead to altered cellular responses that may include the inhibition of C7orf28A activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Another MEK inhibitor that prevents the activation of MAPK/ERK pathway. Disruption of this pathway can lead to changes in cell cycle progression and differentiation, potentially influencing C7orf28A activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor similar to LY294002, which can block the PI3K/AKT pathway and affect various downstream processes that could involve C7orf28A. | ||||||